Announcements Trials

Browse Landscape

Phase

Status

Recruiting 3 Completed 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphangioleiomyomatosis 1

Interventions

Cisplatin 352 Oxaliplatin 262 Capecitabine 258 Radiotherapy 240 Gemcitabine 223 Docetaxel 223 Carboplatin 223 Drug Therapy 219 Cyclophosphamide 219 Paclitaxel 205 apatinib 201 Bevacizumab 196 camrelizumab 190 Fluorouracil 188 sintilimab 133 Irinotecan 125 Blood Specimen Collection 125 Dexamethasone 123 Etoposide 119 Radiosurgery 118 toripalimab 117 Surgical Procedures, Operative 115 pembrolizumab 112 Pemetrexed 108 anlotinib 105 S 1 (combination) 105 Leucovorin 102 Surveys and Questionnaires 101 Nivolumab 98 tislelizumab 96

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × OTHER × Loratadine × Clear all

NCT05190627 2022-01-27

LORALAM

Institut d'Investigació Biomèdica de Bellvitge

Phase 2 Unknown

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡